No abstract

Up to 49% of patients attending radiation therapy appointments may experience anxiety and distress. Anxiety is heightened during the first few visits to radiation oncology. Radiation therapists (RT) are the only health professionals in direct daily contact with patients during treatment, placing them in a unique position to explore patients’ psychosocial needs. This review aims to synthesise literature regarding the effect of RT‐led psychosocial support on patient anxiety. In May 2015, we searched the following electronic databases: Medline, PsycINFO, Embase, CINAHL, PubMed and Cochrane library. Radiation therapy‐specific journals were hand‐searched, and reference lists of identified studies searched. This review complies with Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. The search identified 263 articles, of which 251 were excluded based on non‐English language, duplicate article or relevance. A total of 12 articles involving 1363 patients were included and categorised into three broad themes: ‘Patient Perspectives’ 3 articles, ‘Patient Information and Education’ 5 articles and ‘Screening and Needs Assessment’ 4 articles. Two publications referred to the same sample and data. Quality ratings were mixed, with one study rated ‘high’ quality, seven ‘moderate’ and four ‘low’. Methodological weaknesses were identified in relation to workflow, sample size and responder bias. RTs have a role in psychosocial support through increased communication and information sharing, which can benefit both patients and staff. RT‐led practices such as relationship building, patient education sessions and screening and needs assessments are feasible and can reduce anxiety.

BackgroundRandomized controlled trials have established concurrent chemo-radiotherapy as the preferred treatment option for inoperable local-regionally advanced head and neck squamous cell carcinomas (HNSCCs). Because many patients have multiple co-morbidities and would not fulfill the eligibility criteria of clinical trials, the results need to be re-evaluated in daily clinical practice with special reference to early mortality.Methods167 consecutive patients with HNSCC who received concurrent chemo-radiotherapy at the Basel University Hospital between 1988 and 2006 were analyzed retrospectively with a special focus on early deaths and risk factors for an unfavorable outcome.ResultsIn our cohort, the 3- and 5-year overall survival rates were 54% and 47%, respectively. The therapy was associated with relevant toxicity and an early mortality rate of 5.4%. Patients dying early were analyzed individually for the cause of death. Patients with elevated white blood cell counts (HR: 2.66 p = 0,016) and vascular co-morbidities (HR: 5.3, p = 0,047) showed significantly worse survival rates. The same factors were associated with a trend toward increased treatment-related mortality. The 3-year survival rate improved from approximately 43% for patients treated before the year 2000 to 65% for patients treated after the year 2000 (Fisher’s exact test p = 0.01).ConclusionsAlthough many patients who received concurrent chemo-radiotherapy would not have qualified for clinical trials, the outcome was favorable and has significantly improved in recent years. However the early mortality was slightly worse than what is described in the literature.

No abstract